Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis

Digestive Diseases and Sciences

Volumn 44, Issue 5, 1999, Pages 986-990

  Ware, Jeffrey H ^a   Wan, X Steven ^a   Newberne, Paul ^a   Kennedy, Ann R ^a  

^a 530 Clinical Research Bldg ^*

Author keywords

Bowman Birk inhibitor; Inflammatory bowel disease; Protease inhibitor; Ulcerative colitis

Indexed keywords

BOWMAN BIRK INHIBITOR; DEXTRAN SULFATE; PROTEINASE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; ENZYME INHIBITION; HISTOPATHOLOGY; INFLAMMATION; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ANIMALS; COLITIS, ULCERATIVE; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED STRAINS; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN; TRYPSIN INHIBITORS;

EID: 0032957934     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026616832119     Document Type: Article

References (30)

1. Yavelow J, Collins M, Birk Y, Troll W, Kennedy AR: Nanomolar concentrations of Bowman-Birk soybean protease inhibitors suppress X-ray induced transformation in vitro. Proc Natl Acad Sci USA 82:5395-5399, 1985
2. Kennedy AR: Anticarcinogenic activity of protease inhibitors: Overview. In Protease Inhibitors as Cancer Chemopreventive Agents. W Troll, AR Kennedy (eds). New York, Plenum Press, 1993, pp 9-64
3. Kennedy AR, Szuhaj BF, Newberne PM, Billings PC: Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate. Nutr Cancer 19:281-302, 1993
4. Larionova NI, Gladysheva IP, Tikhonova TV, Kazanskaia NF: Inhibition of cathepsin G and elastase from human granulocytes by multiple forms of the Bowman-Birk type of soy inhibitor. Biochemistry (Moscow) 58:1437-1444, 1993
5. Tikhonova TV, Gladysheva IP, Kazanshaya NF, Larionova NI: Hydrolysis of elastin by human leukocyte elastase and cathepsin G: Inhibition by Bowman Birk type inhibitor. Biochemistry (Moscow) 59:1295-1299, 1994
6. Gladysheva IP, Larionova NI, Gladysheva DP, Tikhonova TV, Kazanskaia NF: The classical Bowman-Birk soy inhibitor is an effective inhibitor of human granulocyte alpha-chymotrypsin and cathepsin G. Biochemistry (Moscow) 59(4):513-518, 1994
7. Ware JH, Wan XS, Rubin H, Schechter NM, Kennedy AR: Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys 344:133-138, 1997
8. Frenkel K, Chrazan K, Ryan CA, Wiesner R, Troll W: Chymotrypsin-specific protease inhibitors decrease H2O2 formation by activated human polymorphonuclear leukocytes. Carcinogenesis 8:1207-1212, 1987
9. Podolsky DK: Inflammatory bowel disease. N Engl J Med 325:928-937, 1008-1016, 1991
10. Glickman RM: Inflammatory Bowel disease: Ulcerative colitis and Crohn's disease. In Harrison's Principles of Internal Medicine. KJ Isselbacher, et al (eds). New York, McGraw-Hill, 1994, pp 1403-1417
11. Bohe M: Pancreatic and granulocytic endoproteases in faecal extracts from patients with active ulcerative colitis. Scand J Gastroenterol 22:59-64, 1987
12. Bohe M, Genell S, Ohisson K: Protease inhibitors in plasma and faecal extracts from patients with active inflammatory bowel disease. Scand J Gastroenterol 21:598-604, 1986
13. Hawkins JV, Emmel EL, Feuer JJ, Nedelman MA, Harvey CJ, Klein HJ, Rozmiarek J, Kennedy AR, Lichtenstein GR, Billings PC: Protease activity in a hapten-induced model of ulcerative colitis in rats. Dig Dis Sci 42:1969-1980, 1996
14. Hanauer SB, Baert F: Medical therapy of inflammatory bowel disease. Med Clin North Am 78:1413-1426, 1994
15. Das KM: Some current perspectives on the etiology and pathogenesis of ulcerative colitis. In Ulcerative Colitis. CA O'Morain (ed). Boca Raton, Florida, CRC Press, 1991, pp 47-54
16. Wargovich MJ, Bauer AR, Hu PJ, Sumiyoshi H: Dietary factors and colorectal cancer. Gastroenterol Clin North Am 7:727-745, 1988
17. Rudolph U, Finegold MJ, Rich SS, Harriman GR, Srinivasan Y, Brabet P, Boulay G, Bradley A, Birnbaumer L: Ulcerative colitis and adenocarcinoma of the colon in G-alpha-i2-deficient mice. Nature Genet 10:143-150, 1995
18. Dayal Y, DeLellis RA: The gastrointestinal tract. In Robbins Pathologic Basis of Disease, RS Cotran, V Kumar, SL Robbins (eds). Philadelphia, WB Saunders, 1989, pp 827-910
19. Pena AS, Shivanada S, Mayberry JF: Epidemiology of ulcerative colitis. In Ulcerative Colitis. CA O'Morain (ed). Boca Raton, Florida, CRC Press, 1991, pp 1-8
20. Senda S, Fujiyama Y, Bamba T, Hosoda S: Treatment of ulcerative colitis with camostat mesilate, a serine protease inhibitor. Intern Med 32:350-354, 1993
21. Birk Y: Proteinase inhibitors from plant sources. Methods Enzymol 45:695-751, 1975
22. Birk Y: The Bowman-Birk inhibitor. Int J Peptide Protein Res 25:113-131, 1985
23. Billings PC, Clair WHS, Maki PA, Kennedy AR: Distribution of the Bowman-Birk inhibitor in mice following oral administration. Cancer Lett 62:191-197, 1992
24. Yavelow J, Finlay TH, Kennedy AR, Troll W: Bowman-Birk soybean protease inhibitor as an anticarcinogen. Cancer Res 43:2454-2459, 1983
25. Billings PC, Brandon DL, Habres JM: Internalization of the Bowman-Birk protease inhibitor by intestinal epithelial cells. Eur J Cancer 27:903-908, 1991
26. Cooper HS, Murthy SNS, Shah RS, Sedergran DJ: Clinicopathologic study of dextran sulfate sodium in experimental murine colitis. Lab Invest 69:238-249, 1993
27. Cooper HS, Murthy SNS: Displasia in dextran sulfate sodium (DSS) experimental murine colitis. Gastroenterology 106:A378, 1994
28. Dielman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO: Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107:1643-1652, 1994
29. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagake Y, Nakaya R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694-702, 1990
30. Zar JH: Biostatistical Analysis, Upper Saddle River, New Jersey, Prentice Hall, 1996